Compare JWEL & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JWEL | PPCB |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.7M |
| IPO Year | 2021 | N/A |
| Metric | JWEL | PPCB |
|---|---|---|
| Price | $2.13 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 270.0K |
| Earning Date | 05-12-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,450,865.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $0.24 |
| 52 Week High | $3.24 | $145.46 |
| Indicator | JWEL | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 22.64 |
| Support Level | $2.06 | $0.24 |
| Resistance Level | $2.23 | $0.34 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.21 | 18.88 |
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing. Geographically, it generates all of its revenue from the PRC.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.